Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics, Inc. (“Neoleukin” or the “Company”) (Nasdaq: NLTX), priced its $75.0 million follow-on offering on December 17, 2019 at a price of $8.40 per share. The Company issued 8,925,000 shares of common stock. Neoleukin intends to use the net proceeds from the offering, together with its existing cash resources, to advance development of its lead program, NL-201, to expand its de novo protein design technology, to develop its preclinical pipeline and to fund working capital and for general corporate purposes, including capital improvements to properties it leases.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.